After beating "historical" Xtandi masofaniten fails to beat actual Xtandi.

October's US approvals included Scemblix, Vyloy and Itovebi, while Lumakras was delayed.

The group goes after a KRAS-related target on which Boehringer recently gave up.

Conferences ramp up, and ASH abstracts near.

Pelabresib is delayed, and Novartis writes off $800m of the €2.7bn purchase.

RMC-9805 looks more efficacious, and less toxic, than Astellas’s G12D degrader in pancreatic cancer.

There’s little to distinguish the two HIF2α inhibitors in kidney cancer.

The company reckons it’s got what it takes to hit the right member of the FGFR family.

AKY-1189 could be used in Padcev-relapsed patients, and in cancers beyond bladder.

ZL-1310 looks better than other DLL3-targeting agents, but two thirds of responses are so far unconfirmed.